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Reassessing Rabbit Antithymocyte Globulin 
Induction in Kidney Transplantation (RETHINK): 
An Analysis of the North American Pediatric 
Renal Trials and Collaborative Studies 
(NAPRTCS) Registry
Isa F. Ashoor, MD,1 Karen Martz, MS,2 Shirley Galbiati, MS,2 Robbie A. Beyl, PhD,3  
and Vikas R. Dharnidharka, MD, MPH;4 on behalf of the NAPRTCS Investigators*
INTRODUCTION
Short-term pediatric kidney transplant recipient outcomes 
have significantly improved over the years with enhanced 
surgical techniques and more potent immunosuppres-
sion.1 The use of lymphocyte-depleting induction immu-
nosuppression has led to significant reduction in first-year 
Pediatric Transplantation
Background. There is no consensus on rabbit antithymocyte globulin (rATG) dose used for induction immunosuppres-
sion in pediatric kidney transplants. We aimed to identify whether a lower rATG dose provides safe and effective immunosup-
pression compared with a higher dose. Methods. We retrospectively analyzed all first-time kidney transplant recipients 
(aged <21 y) in the North American Pediatric Renal Trials and Collaborative Studies registry since 1998 on mycophenolate 
mofetil– and tacrolimus-based immunosuppression with rATG induction. An a priori cutoff of 7.5 mg/kg cumulative rATG 
dose was used to identify low (<7.5 mg/kg) and high (≥7.5 mg/kg) exposure groups. Primary outcome was time to first-
acute rejection episode. Secondary outcomes included graft function, patient survival, hospitalizations due to infections, 
and time to first-posttransplant lymphoproliferative disorder episode.  Results. Four hundred fifty-five patients met inclu-
sion criteria (59% male, 49% whites, 26% blacks, 38% living donor source). Median cumulative rATG dose was 6.8 mg/kg 
with a median of 5 doses and a median 1.5 mg/kg/dose introduced at a median of postoperative 0 days. Sixty-four percent 
received <7.5 mg/kg total rATG. There was no difference in age at transplant, gender, race, end-stage renal disease causes, 
or HLA mismatch among groups. Time to first-acute rejection was similar (P = 0.07). There was no significant difference in 
graft or patient survival or time to posttransplant lymphoproliferative disorder. Hospitalization for infection rates was simi-
lar. Conclusions. These data demonstrate a wide variation in cumulative rATG induction dose. A smaller rATG dose 
<7.5 mg/kg may provide effective and safe immunosuppression compared with a higher dose.
(Transplantation Direct 2020;6: e598; doi: 10.1097/TXD.0000000000001042. Published online 21 August, 2020.)
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acute kidney transplant rejection rates2 and allowed many 
pediatric transplant centers to adopt steroid avoidance or 
steroid minimization immunosuppression protocols for 
low-immunologic risk patients.3 Rabbit antithymocyte 
globulin (rATG) is the most commonly used lymphocyte- 
depleting induction therapy in both adult and pediatric kid-
ney transplant recipients.4 However, rATG did not receive 
FDA approval for that induction indication until 2017.5 
This may have contributed to wide variation in “standard” 
dosing practice, as it related to cumulative exposure tar-
gets for induction in kidney transplant recipients as each 
transplant center adopted its own standards and practice.4 
Significant cost savings can be realized with lower cumula-
tive rATG exposure,6 and the inherent risk of infection and 
leukopenia with its use in conjunction with other immu-
nosuppressive drugs favors a more judicious approach in 
dosing and administration.2 However, a lower dosing strat-
egy may carry with it a higher risk of acute rejection given 
rATG’s established superiority in preventing acute rejection 
episodes at a relatively high cumulative dosing threshold 
of 7.5 mg per kg of body weight.7 In this study, we sought 
to evaluate prevailing practice patterns in rATG utilization 
among pediatric kidney transplant centers and to determine 
whether a lower rATG dose may provide safe and effective 
immunosuppression compared with a higher rATG dose.
MATERIALS AND METHODS
Study Design
This is a retrospective registry analysis study utilizing the 
North American Pediatric Renal Trials and Collaborative 
Studies (NAPRTCS) transplant registry. The study protocol 
was submitted to the local institutional review board, which 
deemed the study to be exempt from further review. NAPRTCS 
was founded in 1987 as a voluntary registry to capture current 
practice and trends in immunosuppressive therapy with an 
ultimate goal of improving the care of pediatric renal allograft 
recipients in North America.8 At the time of this analysis, reg-
istry data were complete through end of calendar year 2016.
Inclusion Criteria
We analyzed all first-time pediatric kidney-only transplant 
recipients aged younger than 21 years at the time of trans-
plant who were transplanted in 1998 or later. The analysis 
was limited to those who received rATG induction therapy 
and maintenance immunosuppression with a tacrolimus and 
mycophenolate mofetil (MMF)-based regimen at day 30 post 
index kidney transplant.
Exposure Variable
Based on a single rATG dose of 1.5 mg per kg of body weight, 
rATG cumulative exposure threshold was set a priori at 5 doses 
or greater (≥7.5 mg/kg) for the high-dose exposure group and at 
<5 doses (<7.5 mg/kg) for the low-dose exposure group.
Outcomes
Primary outcome was time to first-acute kidney trans-
plant rejection episode. Secondary outcomes included 6- and 
12-month graft function as measured by the modified Schwartz 
formula in mL/min/1.73m2 as well as comparisons of graft and 
patient survival,9 hospitalizations due to infections, and time 
to first-posttransplant lymphoproliferative disorder (PTLD) 
episode through 5 years post index kidney transplantation.
Statistical Analysis
Categorical demographic and baseline characteristics were 
summarized by exposure group and compared using Pearson’s 
chi-squared test. The amount and duration of rATG dosing 
were summarized numerically by exposure group. Kaplan-
Meier survival curves were generated by exposure group 
for each of the outcome variables of acute rejection, graft 
failure, death, and PTLD. Differences in the distributions of 
time to the outcome variable between exposure groups were 
evaluated using the log-rank test. Time-to-event analyses 
for outcomes of patient and graft survival, acute rejection, 
and PTLD were repeated after controlling for steroid use at 
30 days. The proportions of patients hospitalized within 12 
months of transplant were summarized by exposure group 
and compared with Pearson’s chi-squared test. Estimated 
glomerular filtration rate at 6 and 12 months were summa-
rized numerically by exposure group, and the distributions 
were compared using the Kruskal-Wallis test. Analyses of all 
outcome measures were repeated in a subset analysis that 
excluded patients receiving their first dose of rATG beyond 
7 days post kidney transplant. Additionally, we performed a 
subset analysis of “low-risk” recipients limited to white recip-
ients who did not experience delayed graft function.
RESULTS
Cohort Description and Baseline Characteristics of 
Low-dose and High-dose rATG Exposure Groups
At the time of this analysis, the NAPRTCS registry included 
data on 12 686 kidney transplant recipients, of whom 9826 were 
recipients of their first kidney transplant and aged younger than 
21 years (Table 1). Of those, 486 met criteria for having received 
rATG induction and tacrolimus- and MMF-based maintenance 
regimen at day 30 post index kidney transplant. After exclusion 
of recipients with missing data on rATG dosing, a total of 440 
subjects from 37 participating centers were included in the final 
analysis (Figure 1). Two hundred fifty-seven were male (58%), 
49% were white, 26% black, and 15% Hispanic. Cause of end-
stage renal disease was attributed to congenital anomalies of 
the kidney and urinary tract in 38%, nephrotic syndrome and 
focal segmental glomerulosclerosis in 20%, other glomerulone-
phritis in 16%, and other causes in 28%. Thirty-eight percent 
were living kidney donor recipients. Median age at index kid-
ney transplant was 13 years, and 68% were transplanted in the 
most recent decade of registry data (2006–2016). Most patients 
had 1 or 2 antigen mismatches at the HLA-A (1 mismatch [mm] 
41.6%; 2 mm 38.4%), HLA-B (1 mm 37%; 2 mm 44.8%), 
and HLA-DR (1 mm 43.6%; 2 mm 34.3%) loci. Most patients 
received prophylactic antibiotics (92%) and steroid mainte-
nance immunosuppression at day 30 posttransplant (75.7%). 
Delayed graft function was observed in 10% of patients during 
their index kidney transplant hospitalization.
Using an a priori cutoff of 7.5 mg/kg cumulative rATG 
induction dose to stratify the cohort, we identified 64% that 
received <7.5 mg/kg cumulative rATG (low-dose exposure 
group) and 36% that received ≥7.5 mg/kg cumulative rATG 
(high-dose exposure group). The low-dose group received a 
median of 4 days of rATG therapy with a median cumulative 
exposure of 5.8 mg/kg versus a median of 6 days of therapy 
and 9.1 mg/kg cumulative exposure for the high-dose group. 
There was no significant difference between both groups in 
terms of age at time of transplant, gender, race, donor source, 
primary end-stage renal disease cause, degree of HLA-A, B, or 
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DR mismatch, and use of prophylactic antibiotics. However, a 
higher proportion of the low-dose exposure group was trans-
planted in the most recent era (P = 0.001) and was steroid free 
at day 30 post kidney transplant compared with the high-dose 
exposure group (31% versus 13%; P < 0.001). Delayed graft 
function was significantly higher in the high-dose exposure 
group (18% versus 6%; P < 0.001).
rATG Dosing Trends
For the entire cohort, the median cumulative rATG dose was 
6.8 mg/kg (range 0.8–23.8 mg/kg) with a median of 5 doses 
(range 1–20) and a median of 1.5 mg/kg/dose (range 0.4–3.1) 
introduced at a median of postoperative 0 days (range 0–15) 
(Figure S1, SDC, http://links.lww.com/TXD/A270). In the 
registry period analyzed, rATG cumulative exposure dose has 
declined from an average median of 7.9 mg/kg in the period 
from 1999 to 2008 to 6.3 mg/kg in the period from 2009 to 
2016 (Figure S2, SDC, http://links.lww.com/TXD/A270).
Comparison of Graft and Patient Outcomes Between 
Low-dose and High-dose rATG Exposure Groups
Time to first episode of acute rejection was similar in both 
groups as shown in Figure 2, with a Kaplan-Meier estimate 
with log-rank P value of 0.07. There was a tendency toward 
an earlier occurrence of the first episode of acute rejection in 
the high-dose exposure group with 13.8% and 20.7% reach-
ing that outcome at 6 and 12 months, respectively, relative to 
6.8% and 12.7% in the low-dose exposure group. Similarly, 
there was no difference in graft survival between both groups 
through 5 years of follow-up, P value 0.05, although subjects 
in the low-dose exposure group tended to have slightly better 
graft survival at most time points posttransplant (Figure 3). 
There was no significant difference in patient survival between 
groups (P = 0.93) (Figure 4). Time to occurrence of PTLD was 
not significantly different between groups (P = 0.07), although 
all cases recorded in the registry were in the low-dose expo-
sure group (Figure  5). When the time-to-event analyses 
described above were repeated controlling for steroid use at 
30 days, the findings did not change (time to first episode of 
acute rejection, P = 0.2; graft survival, P = 0.06; patient sur-
vival, P = 0.9; and time to occurrence of PTLD, P = 0.08). All 
time-to-event outcome measures were then repeated after 
exclusion of patients receiving their first dose of rATG beyond 
7 days post kidney transplant (n = 21) and yielded no statisti-
cally significant differences (data not shown). Hospitalization 
rates due to infections were similar in both exposure groups 
at 6 and 12 months posttransplant at around 20%, P value 
0.98 (Table S1, SDC, http://links.lww.com/TXD/A270). 
Finally, the low-dose exposure group had better graft function 
at both 6 and 12 months posttransplant (67.1 and 65.5 mL/
min/1.73m2, respectively) relative to the high-dose exposure 
group (63.5 and 62.5 mL/min/1.73m2, respectively), P value 
0.03 (at 6 mo) and 0.04 (at 12 mo; Table S2, SDC, http://links.
lww.com/TXD/A270). Subset analysis of a “low-risk” cohort 
comprising white recipients who did not experience delayed 
graft function revealed no statistically significant differences 
in any of the outcome measures above between the low- and 
high-dose exposure groups while eliminating all differences 
in baseline characteristics including transplant era (data not 
shown).
DISCUSSION
This is the first study to examine the use of rATG induction 
for first-time pediatric kidney transplant recipients in a large 
pediatric-specific registry. rATG use has increased over time, 
and it is currently the most commonly used induction ther-
apy for kidney transplantation.4 However, the lack of specific 
dosing recommendations until very recently has led to many 
immunosuppressive protocols in the adult transplant literature 
with an overall trend toward a lower cumulative exposure in 
the most recent era.6,10–12 By utilizing the NAPRTCS registry, a 
large voluntary database that collects information on pediat-
ric kidney transplants performed across North America,8 we 
provide a contemporary assessment of the prevailing practice 
patterns at 37 participating centers with regards to rATG use 
for induction therapy. We demonstrate a wide variability in 
rATG cumulative exposure between individual centers, yet 
TABLE 1.




<7.5 mg/kg,  
rATG,  
N = 281 (64%)
High-dose 
group  
≥7.5 mg/kg,  
rATG,  
N = 159 (36%) P
Age at index transplant, n (%) (y)    
 0–1 8 (3%) 6 (4%)  
 2–5 34 (12%) 24 (15%) 0.43
 6–12 98 (35%) 45 (28%)  
 13–20 141 (50%) 84 (53%)  
Gender: male, n (%) 157 (56%) 102 (64%) 0.1
Race/ethnicity, n (%)    
 White 141 (50%) 72 (45%)  
 Black 70 (25%) 48 (30%) 0.66
 Hispanic 42 (15%) 22 (14%)  
 Other 28 (10%) 17 (11%)  
Living donor recipient, n (%) 112 (40%) 56 (35%) 0.34
Transplant era, n (%)    
 Before 2001 8 (3%) 8 (5%)  
 2001–2005 70 (25%) 56 (35%)  
 2006–2010 121 (43%) 76 (48%) 0.001
 After 2010 82 (29%) 19 (12%)  
HLA mismatch, n (%)    
 HLA-A (mm)    
  0 22 (8%) 10 (6%)  
  1 124 (44%) 75 (47%) 0.1
  2 96 (34%) 57 (36%)  
  Missing 39 (14%) 17 (11%)  
 HLA-B (mm)    
  0 14 (5%) 11 (7%)  
  1 110 (39%) 53 (33%) 0.23
  2 118 (42%) 78 (49%)  
  Missing 39 (14%) 17 (11%)  
 HLA-DR (mm)    
  0 22 (8%) 16 (10%)  
  1 120 (43%) 72 (45%) 0.55
  2 97 (34%) 54 (34%)  
  Missing 42 (15%) 17 (11%)  
Steroid-free at day 30 posttransplant, 
n (%)
86 (31%) 21 (13%) <0.001
Received prophylactic antibiotics, n (%) 256 (91%) 149 (94%) 0.2
Developed delayed graft function, n (%) 17 (6%) 29 (18%) <0.001
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an overall trend toward lower exposure in the most recent 
era. This is consistent with a recent large-scale analysis of the 
Scientific Registry of Transplant Recipients that encompassed 
166 776 US recipients between 2005 and 2014.4 Similar to 
evolving trends toward lower rATG exposure in adult centers, 
most recipients in our analysis received <7.5 mg/kg of cumula-
tive rATG induction therapy, suggesting a shift to a total of 4 
doses or less at 1.5 mg/kg each.
One concern related to lower rATG dose exposure is the 
possible increased risk in acute rejection and how that may 
impact graft survival. Several studies have demonstrated 
excellent 1-year graft outcomes with low-dose rATG induc-
tion strategies. In a comparison to conventional rATG 
exposure targets of 6–10 mg/kg, Singh et al6 reviewed their 
outcomes using a tailored rATG cumulative exposure target 
of 3–6 mg/kg over a 5-year period and found comparable 
FIGURE 2. Time to first episode of acute rejection.
FIGURE 1. Analysis strategy. MMF, Mycophenolate mofetil; NAPRTCS, North American Pediatric Renal Trials and Collaborative Studies; and 
rATG, rabbit anti-thymocyte globulin.
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outcomes to those reported in the Scientific Registry of 
Transplant Recipients. Another study by Grafals et al12 uti-
lizing a much lower rATG cumulative exposure target of 
either 2.25 or 3.75 mg/kg demonstrated a biopsy-proven 
acute rejection rate of 10% and 17%, respectively, at 1-year 
follow-up and similar T-cell subpopulation depletion and 
repopulation kinetics in both groups. Long-term outcome 
data are similarly encouraging with a study of 145 adult 
kidney transplant recipients who received low-dose rATG 
induction (total cumulative exposure of 3–5 mg/kg), demon-
strating superior 8-year graft survival for recipients of both 
deceased and living donor kidneys compared with those 
receiving basiliximab induction.11 Although pediatric data 
comparing rATG induction to basiliximab induction out-
comes is limited, Crowson et al13 identified a lower risk of 
acute rejection in African American pediatric kidney trans-
plant recipients induced with depleting agents that included 
rATG and alemtuzumab relative to nondepleting agents that 
included basiliximab and daclizumab. In our study, there was 
no difference in the time to first episode of acute rejection 
between the low- and high-rATG exposure groups. In fact, 
we noted a trend toward earlier onset of acute rejection epi-
sodes in the high-dose exposure group. We hypothesized this 
may have been in part due to differences in baseline charac-
teristics of both groups, with the high-dose exposure group 
reflecting a relatively older transplant era cohort and with a 
higher proportion of patients who experienced delayed graft 
function. Further analysis of a “low-risk” cohort limited to 
white recipients and excluding patients with delayed graft 
function eliminated those baseline differences between the 
low- and high-dose exposure groups and upheld the original 
analysis finding of no difference in time to first episode of 
acute rejection between groups. Graft survival in our study 
was similar in both the low-dose and high-dose exposure 
groups through 5 years of follow-up.
Another major concern with lymphocyte depleting 
induction therapy is the higher risk of opportunistic infec-
tion and possible increase in malignancy rates particularly 
PTLD.2,14,15 Further intensification of immunosuppression in 
recipients who develop acute rejection episodes can further 
compound that risk. Our study did not identify a difference 
in rate of hospitalizations due to infections between groups. 
Although not statistically significant, one potential concern 
is the aggregation of all PTLD cases in the low-dose expo-
sure arm. Given the lack of granular data regarding Epstein–
Barr virus recipient and donor mismatch in the NAPRTCS 
registry, it is difficult to ascertain the significance of this 
finding. Additionally, the registry lacked detailed descrip-
tions of oral maintenance immunosuppression burden, 
such as drug dosage and therapeutic drug levels, to allow 
further examination of this trend. Nevertheless, the occur-
rence of PTLD underscores the inherent risks associated 
with rATG induction and immunosuppression in general, 
and we need to pursue evidence-based strategies to lower 
cumulative immunosuppression exposure in low-risk pedi-
atric recipients. One potential strategy may involve tailored 
FIGURE 3. Graft survival.
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FIGURE 4. Patient survival.
FIGURE 5. Time to first episode of PTLD. PTLD, posttransplant lymphoproliferative disorder.
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rATG dosing based on individual recipient T-cell depletion 
kinetics as determined by daily measurement of peripheral 
blood CD3 T-cell subset counts. This has been piloted suc-
cessfully in adult kidney transplant recipient cohorts in 
which intermittent rATG doses were administered when the 
CD3 count exceeded a predefined threshold of either 10 or 
20 cells/mm3 depending on the cohort, resulting in adequate 
T-cell depletion and significant reduction in cumulative 
exposure and therapy cost compared with standard daily 
dosing.16,17 Pediatric experience in this regard is limited and 
would benefit from a prospective study design to assess the 
safety and efficacy of a similar personalized approach. The 
NAPRTCS registry did not collect data on CD3 counts, and, 
as such, a description of T-cell depletion kinetics relative to 
rATG induction dose is not possible.
Our study has several limitations: Although the 
NAPRTCS registry collects data from many pediatric kid-
ney transplant centers in North America, it is a voluntary 
registry and as such, is not inclusive of all practice pat-
terns regarding rATG use, particularly those from smaller 
institutions that may not be contributing to the registry. 
The retrospective registry data limits the ability to draw 
firm conclusions regarding causation as it relates to out-
comes and rATG cumulative exposure, although the trends 
observed are encouraging to pursue those questions in a 
prospective manner. Also, registry data are limited by lack 
of granular outcomes not collected by the registry, such 
as data on leukopenia, viremia, and donor-specific anti-
body screens. However, the robust registry infrastructure 
of NAPRTCS and longitudinal data collection dating back 
to 1998 for our study allows a comprehensive analysis of 
time trends and long-term outcomes that would be diffi-
cult to accomplish with other study designs. Of note, our 
eligible subject number was significantly lower than the 
total registry count for subjects receiving rATG induction 
due to the inclusion criteria requirement of a tacrolimus- 
and MMF-based maintenance regimen. We believe limit-
ing our analysis to this subset provides the most relevant 
outcomes data reflective of contemporary immunosuppres-
sion practice patterns at most pediatric kidney transplant 
centers in the current era. Our analysis is also limited in 
its ability to provide generalizations applicable to recipi-
ents on steroid-free immunosuppression protocols given 
that most patients (75.7%) were still receiving steroids 
at day 30 posttransplant. However, the comparable acute 
rejection outcomes between the low- and high-dose rATG 
exposure groups despite a relatively higher proportion of 
steroid-free recipients in the low-dose exposure group sug-
gests that steroid-free immunosuppression protocols did 
not have a negative detrimental effect on graft outcomes 
in those patients. Similarly, controlling for steroid use at 
day 30 post kidney transplant did not significantly alter 
our findings. Finally, we were unable to compare outcomes 
between rATG induction in either dose group to outcomes 
in recipients induced with nondepleting agents (such as 
basiliximab) or no induction at all, as that was beyond the 
scope of this registry analysis, although we look forward to 
examining those differences in future studies.
In conclusion, we have demonstrated a wide variability 
in rATG cumulative exposure for induction immunosup-
pression in first-time pediatric kidney transplant recipients 
with an overall trend toward lower exposure in the most 
recent era that does not appear to be associated with infe-
rior graft and recipient outcomes in this registry. Future 
studies should utilize more granular outcome measures such 
as development of viremia, leukopenia, and donor-specific 
antibodies in relation to various rATG exposure thresholds. 
This will inform future practice regarding optimal rATG 
induction therapy dosing in low-risk pediatric kidney trans-
plant patients without compromising graft and recipient 
outcomes.
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Hunt
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84 Rainbow Babies Children’s Hospital Tamar Springel
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157 Arnold Palmer Children’s Hospital Jorge Ramirez
158 Children’s Specialty Center Randall Jenkins
159 Pediatric Nephrology of Alabama Mark Benfield
161 St. Vincent Hospital Daniel McKenney
162 Memorial Health System Alexandru Constantinescu
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164 Children’s Kidney Center of Florida Deogracias Pena
167 Helen De Vos Children’s Hospital Alejandro Quiroga Julia 
Steinke
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Center 
No. Center Name Current PI
1 Boston Children’s Hospital Michael Somers
2 Duke University Annabelle Chua
3 University of Virginia John Barcia
4 Cincinnati Children’s Hospital Medical Center David Hooper
5 Phoenix Children’s Hospital Gina-Marie Barletta Martin 
Turman
6 Children’s Hospital of the King’s Daughters Irene Restaino
7 SUNY Buffalo Sudha Garimella
8 Cardinal Glennon Children’s Hospital Craig Belsha
9 Virginia Commonwealth University Megan Lo
11 Hospital for Sick Children Elizabeth Harvey
12 University of California Los Angeles Isidro Salusky Ora Yadin
13 University of California San Francisco Marsha Lee
14 Lurie Children’s Hospital Craig Langman
15 Johns Hopkins University Meredith Atkinson
16 Emory Laurence Greenbaum
18 Children’s Mercy Kansas City Bradley Warady
19 University of Wisconsin Sharon Bartosh
20 Children’s Medical Center Dallas Mouin Seikaly
21 SUNY Brooklyn Anil Mongia
23 University of Texas Health Science Center 
Houston
Rita Swinford
24 LeBonheur Children’s Hospital Ali Mirza Onder
25 Children’s Hospital of British Columbia Tom Blydt-Hansen
27 University of Nebraska Helen Lovell
29 University of Minnesota Michelle Rheault
30 Cornell Juhi Kumar
31 University of Iowa Kathy Lee-Son
32 University of Missouri Laura Hesemann
33 University of California San Diego Nadine Benador
34 University of Texas Health Science Center San 
Antonio
Mazen Arar
35 University of Miami Carolyn Abitbol
36 University of Michigan Kera Luckritz
37 Mt. Sinai Corinne Benchimol
38 University of Alabama Birmingham Sahar Fathallah-Shaykh
41 Seattle Children’s Hospital Joseph Flynn
43 Children’s Hospital Medical Center of Akron Rupesh Raina
44 University of Mississippi Mehul Dixit
45 Children’s Hospital Wisconsin Cynthia Pan
47 Nationwide Children’s Hospital Hiren Patel
50 Children’s Hospital Michigan Gaurav Kapur
51 University of Illinois Kimberly Czech
52 Mayo Clinic Carl Cramer
53 Massachusetts General Hospital Amita Sharma
55 Children’s Hospital Los Angeles Gary Lerner Carl Grushkin
56 St. Louis Children’s Hospital S. Paul Hmiel Vikas 
Dharnidharka
57 Wake Forest University Ashton Chen
58 Children’s Hospital of Colorado Jens Goebel
59 East Carolina University Guillermo Hidalgo
63 Children’s National Medical Center Asha Moudgil
64  Children’s Hospital Arkansas Eileen Ellis Richard 
Blaszak
65 University of Oklahoma Anjali Nayak
66 University of Utah Raoul Nelson
67 Oregon Health and Science University Kelsey Richardson
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